🔗 Share this article

As America proceeds with historic adjustments to its vaccine guidelines, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by casting doubt on Covid vaccinations during the pandemic and has concentrated on alleged fatalities following Covid vaccination in her recent time at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Health officials were set to unveil radical changes to the pediatric immunization program in December, bringing the US with Denmark’s national calendar, sources say – a major change that would place the US at odds with many the international standard with insufficient data for benefit. The announcement has been postponed until the next year.

In place of the director of the vaccine center, Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to lead the division this calendar year.

A New Direction at the FDA

This interim role might represent a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon dismantling already-approved vaccines at the FDA.

The new acting director has often pushed for halting specific pediatric immunization guidelines in the US so as to align more similar to the Danish model, a country with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

So far statements, she has continued to focus on immunizations – typically the responsibility of Prasad, head of the FDA’s vaccine center – rather than medication approval.

Concerns Over Background

Høeg has little discernible experience in medication creation, regulation or leadership, which has been standard for former leaders of the biologics center. She has served at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past heads of the center would “understand laws and regulations and the underlying principles of medication creation”, noted Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who headed the center have had.”

CDER has an immense portfolio at the FDA, she emphasized.

“Many people just pays attention on the innovative therapies, but the off-patent medication office approves thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and each of these must be supervised,” Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a major leadership aspect to the role, which oversees in excess of 5,000 personnel. “It’s a huge management job, if you execute it properly,” Woodcock added.

Agency Reaction and Contentious Programs

When asked about inquiries about Høeg’s credentials and whether this selection represents greater collaboration among regulatory chiefs on vaccines, a press secretary stated that the “questions are based on flawed presumptions”.

“Her resume matches the responsibilities of her job,” the official stated, citing the time Høeg spent counseling the agency head on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg inherits the agency head's controversial fast-track approval initiative, a contentious rapid therapy clearance system that allegedly concerned her former heads. “By what process are these drugs being picked for this expedited pathway? Who makes the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards less stringent regulations of pharmaceuticals, except for vaccines.”

Established History on Immunizations

Concerning vaccines, Høeg has a clearer, if concerning, history, some experts observe. She published a research paper using non-validated public submissions to determine the frequency of myocarditis following COVID-19 vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming federal leadership featured altering guidelines for new vaccines and ending “unnecessary” vaccines, she stated after the election on a podcast. At the agency, Høeg has allegedly suggested excluding teenage boys from obtaining Covid vaccines.

“She is an all-around ideologue who begins with her preconceived notions and reverse-engineers to fit the evidence in a extremely misleading, untruthful way,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|